Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse

Journal of Veterinary Pharmacology and Therapeutics

Volumn 20, Issue 4, 1997, Pages 296-307

  Cunningham, F M ^a   Andrews, M ^a   Landoni, M F ^b   Lees, P ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; BAY Y 1015; CALCIMYCIN; LEUKOTRIENE B4; LEUKOTRIENE C4; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENANTIOMER; EOSINOPHIL; FEMALE; HORSE; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPHIL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0030747610     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.1997.00064.x     Document Type: Article

References (30)

1. Barnes, N.C. & Kuitert, L. (1994) Influence of leukotriene antagonists on baseline pulmonary function and asthmatic responses. In Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Eds Dahlen, S-E., Hedqvist, P., Samuelsson, B., Taylor, W.A. & Fritsch, J. pp. 217-226. Raven Press, New York.
2. Beckermann, B., Beneke, M., Boettcher, M., Dietrich, H., Horstmann, R. & Seitz, I. (1993) Influence of formulation, food or antacids on the pharmacokinetics of BAY X 1005 in human volunteers. Naunyn Schmiedeberg's Archives Pharmacodynamie, 347, (Suppl.), R27.
3. Cook, W.R. (1976) Chronic bronchitis and alveolar emphysema in the horse. Veterinary Record, 99, 448-451.
4. Copp, F.C., Islip, P.J. & Tateson, J.E. (1984) 3-N-substituted-amino-1 (3-[trifluoromethyl] phenyl)-2-pyrazolines have enhanced activity against arachidonate 5-lipoxygenase and cyclo-oxygenase. Biochemical Pharmacology, 33, 339-340.
5. Doucet, M.Y., Jones, T.R. & Ford-Hutchinson, A.W. (1990) Responses of equine trachealis and lung parenchyma to methacholine, histamine, serotonin, prostanoids and leukotrienes in vitro. Canadian Journal of Physiology and Pharmacology, 68, 379-383.
6. Fairbairn, S.M., Page, C.P., Lees, P. & Cunningham, F.M. (1993) Early neutrophil but not eosinophil or platelet recruitment to the lungs of allergic horses following antigen exposure. Clinical and Experimental Allergy, 23, 821-828.
7. Fischer, A.R., Drazen, J.M., Roth, M., Rosenberg, M.A., Loper, M., Jungerwirth, S. & Israel, E. (1994) The effect of a leukotriene synthesis inhibitor, BAY X 1005 on bronchoconstriction induced by cold, dry air hyperventilation in asthmatics. American Journal of Respiratory Critical Care Medicine, 149, A1056.
8. Fruchtmann, R., Mohrs, K.-H., Hatzelmann, A., Raddatz, S., Fugmann, B., Junge, B., Müller-Peddinghaus, R. & Horstmann, H. (1993) In vitro pharmacology of BAY X 1005, a new inhibitor of leukotriene synthesis. Agents Actions, 38, 188-195.
9. Gillard, J., Ford-Hutchinson, A.W., Chan, C., Charleson, S., Denis, D., Foster, A., Fortin, R., Leger, S., McFarlane, C.S., Morton, H., Piechuta, H., Riendeau, D., Rouzer, C.A., Rokach, J., Young, R., MacIntyre, D.E., Peterson, L., Bach, T., Eiermann, G., Hopple, S., Humes, J., Hupe, L., Luell, S., Metzger, J., Meurer, R., Miller, D.K., Opas, E. & Pacholock, S. (1989) L-663, 536 (MK-886) (3-[1- (4-chlorobenzyl)-3-6-butyl-thio-5-isopropylindol-2-yl]-2, 2-dimethyl-propanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Canadian Journal of Physiology and Pharmacology, 67, 456-464.
10. 2 alpha in epidermis of psoriasis. Proceedings of the National Academy of Sciences, USA, 72, 5130-5134.
11. Hatzelmann, A., Fruchtmann, R., Mohrs, K.H., Raddatz, S. & Müeller-Peddinghaus, R. (1993) Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 {(R)-2-[4- (quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds. Biochemical Pharmacology, 45, 101-111.
12. Hatzelmann, A., Fruchtmann, R., Mohrs, K.H., Raddatz, S., Matzke, M., Pleiss, U., Keldenich, J. & Müller-Peddinghaus, R. (1994a) Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. In Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Eds Dahlen, S-E., Hedqvist, P., Samuelsson, B., Taylor, W.A. & Fritsch, J. pp. 23-32. Raven Press, New York.
13. Hatzelmann, A., Fruchtmann, R., Mohrs, K.H., Raddatz, S., Matzke, M., Pleiss, U., Keldenich, J. & Müller-Peddinghaus, R. (1994b) Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: Implications for biological regulation of 5-lipoxygenase. Agents Actions, 43, 64-68.
14. 4. Biochemical Pharmacology, 48, 31-39.
15. Higgins, A.J., Lees, P. & Wright, J.A. (1984) Tissue-cage model for the collection of inflammatory exudate in ponies. Research in Veterinary Science, 36, 284-289.
16. Higgins, A.J., Lees, P., Sedgwick, A.D., Buick, A.R. & Churchus, R. (1987) Use of a novel non-steroidal anti-inflammatory drug in the horse. Equine Veterinary Journal, 19, 60-66.
17. Horstmann, R., Beckermann, B., Seitz, I., Dietrich, G., Böttcher, M., Lemm, G. & Beneke, M. (1993) Tolerability and pharmacokinetics of the new leukotriene synthesis inhibitor BAY X 1005. Naunyn Schmiedeberg's Archives Pharmacodynamie, 347, (suppl.), R34.
18. Hui, K.P., Binks, S. & Barnes, N.C. (1991) Effect of a cysteinyl-leukotriene antagonist on resting bronchomotor tone in asthmatics. American Review of Respiratory Diseases, 143, A599.
19. Kast, R., Fruchtmann, R., Kupferschmidt, R., Mohrs, K.H., Raddatz, S., Müller-Peddinghaus, R. & Hatzelmann, A. (1994) Role of 5-lipoxygenase-activating protein in the regulation of 5-lipoxygenase activity in human neutrophils. Agents Actions, 41, C166-C168.
20. Lees, P., Taylor, J.B.O., Higgins, A.J. & Sedgwick, A.D. (1988) In vitro and in vivo studies on the binding of phenylbutazone and related drugs to equine feeds and digesta. Research in Veterinary Science, 44, 50-56.
21. Manning, P.J., Watson, R.M., Margolskee, D.J., Williams, V.C., Schwartz, J.I. & O'Bryne, P.M. (1990) Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. New England Journal of Medicine, 323, 1736-1739.
22. 4 receptor antagonist. Annals of the New York Academy of Sciences, 629, 148-156.
23. 4 on bronchoconstriction and radiolabelled neutrophil accumulation in the horse. American Journal of Respiratory Critical Care Medicine, 151, A825.
24. Matzke, M., Beckerman, B., Fruchtmann, R., Burkhard, F., Gardiner, P.J., Goossens, J., Hatzelmann, A., Junge, B., Keldenich, J., Kohlsdorfer, C., Mohrs, K-H., Müller-Peddinghaus, R. & Raddatz, S. (1995) Leukotriene synthesis inhibitors of the quinolone type: parameters for the optimization of efficacy. Proceedings of the XIIIth International Symposium on Medicinal Chemistry. European Journal of Medicinal Chemistry, 30 (suppl), 442s-451s.
25. Meltzer, S.S., Johns, M.A., Rechtsteiner, E.A., Jungerwirth, S., D'Amico, J.M. & Bleecker, E.R. (1994) Bronchodilatory effects of BAY X 1005, a 5-lipoxygenase inhibitor in mild to moderate asthma. Journal of Allergy and Clinical Immunology, 93, 294 (A792).
26. Müller-Peddinghaus, R., Fruchtmann, R., Ahr, H.-J., Beckermann, B., Buehner, K., Fugmann, B., Junge, B., Matzke, M., Kohlsdorfer, C., Raddatz, S., Theisen-Popp, P. & Mohrs, K.-H. (1993a) BAY X 1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. Journal of Lipid Mediators, 6, 245-248.
27. Müller-Peddinghaus, R., Kohlsdorfer, C., Theisen-Popp, P., Fruchtmann, R., Perzborn, E., Beckermann, B., Buehner, K., Ahr, H.J. & Mohrs, K.-H. (1993b) BAY X 1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 267, 51-57.
28. Surette, M.E., Odeimat, A., Palmantier, R., Marleau, S., Poubelle, P.E. & Borgeat, P. (1994) Reverse-phase high-performance liquid chromatography analysis of arachidonic acid metabolites in plasma after stimulation of whole blood ex vivo. Analytical Biochemistry, 216, 392-100.
29. Taylor, I.K., O'Shaughnessy, K.M., Fuller, R.W. & Dollery, C.T. (1991) Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperactivity in atopic subjects. Lancet, 337, 690-694.
30. Virchow, J.C. Jr, Noller, P.S., Wiessmann, K.J., Buhl, R., Thalhofer, S., Dorow, G., Kunkel, G., Ukena, D., Ulbrich, E., Sybrecht, G. & Matthys, H. (1995) Multicenter trial of BAY X 1005, a new 5-lipoxygenase activating protein (FLAP) inhibitor in the treatment of chronic asthma. American Journal of Respiratory Critical Care Medicine, 151, A377.